Crescent Biopharma
CBIO
63 hedge funds and large institutions have $477M invested in Crescent Biopharma in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 8 reducing their positions, and 11 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
67% more capital invested
Capital invested by funds: $286M → $477M (+$191M)
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
9% more funds holding
Funds holding: 58 → 63 (+5)
6.65% more ownership
Funds ownership: 87.52% → 94.17% (+6.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$16.1M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.3M |
| 3 |
Millennium Management
New York
|
+$3M |
| 4 |
Goldman Sachs
New York
|
+$2.33M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$6.38M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$3.59M |
| 3 |
HCM
Heights Capital Management
San Francisco,
California
|
-$3.13M |
| 4 |
PA
Perceptive Advisors
New York
|
-$2.83M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.63M |
CBIO Hedge Fund Activity: Q1 2026 in Review
63 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q1 2026, worth a combined $477M — up 67% from $286M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new CBIO positions and 11 closed out — a net gain of 6 holders — while 18 added to existing stakes and 8 trimmed.
The largest buyer was Balyasny Asset Management, adding an estimated $16.1M. The largest seller was ADAR1 Capital Management, cutting an estimated $6.38M.
- 63 institutional investors held Crescent Biopharma (CBIO) as of Q1 2026, up from 58 in Q4 2025.
- Funds reported $477M of Crescent Biopharma stock for Q1 2026, up 67% quarter-over-quarter.
- 17 funds opened new Crescent Biopharma positions in Q1 2026 and 11 closed out, a net change of +6 holders.
- The largest Crescent Biopharma buyer in Q1 2026 was Balyasny Asset Management, an estimated $16.1M added.
- The largest Crescent Biopharma seller in Q1 2026 was ADAR1 Capital Management, an estimated $6.38M sold.
Based on aggregated 13F filings for Q1 2026.